Article

Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
American Journal of Clinical Pathology (Impact Factor: 3.01). 03/2006; 125(2):273-81. DOI: 10.1309/M9FQ-MQGF-6616-7N2X
Source: PubMed

ABSTRACT In myeloproliferative disorders (MPDs), basophils typically increase in number in the bone marrow (BM) and blood. In chronic myeloid leukemia (CML), basophilia is a diagnostic and prognostic variable. However, no reliable approach for routine detection and enumeration of basophils in BM sections is available. We applied the antibasogranulin antibody BB1 on paraffin-embedded BM sections in 21 control samples (normal BM), 45 patients with CML, 9 with chronic idiopathic myelofibrosis, 11 with polycythemia vera, 19 with essential thrombocythemia, and 7 with indolent systemic mastocytosis. As assessed by immunostaining of serial BM sections, BB1+ cells coexpressed myeloperoxidase, histidine decarboxylase, and leukosialin but did not express B- or T-cell-restricted antigens. BB1+ BM cells were found to be highly elevated in patients with CML compared with normal BM or other MPDs, with maximum counts found in accelerated phase CML (median, 160 cells/mm(2)). In summary, BB1 (basogranulin) is a new immunohistochemical basophil marker that should allow quantification of basophils in CML at diagnosis and during therapy.

0 Bookmarks
 · 
130 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Myelodysplastic syndromes (MDS) comprise a group of clonal hematopoietic stem cell disorders characterised by dysplasia in at least one major myeloid cell line and signs of bone marrow insufficiency with subsequent cytopenia. The updated WHO classification of MDS defines several subtypes including refractory cytopenia (anemia, neutropenia and/or thrombocytopenia), refractory anemia (RA) with ring sideroblasts (RARS), refractory cytopenia with multilineage dysplasia and RA with excess of blast cells (RAEB). While isolated recfractory neutropenia and thrombocytopenia are very rare disease categories, refractory cytopenia with multilineages dysplasia, RARS and refractory anemia with excess of blasts are much more frequently observed. One peculiar subtype of MDS is defined by the presence of an isolated cytogenetic abnormality, in particular del(5q). The diagnostic approach to MDS should include not only cytomorphological evaluation of blood and bone marrow smears but also histological analysis of a bone marrow trephine biopsy specimen and molecular/cytogenetic findings. Some rare subvariants of MDS are not included in the WHO classification system but represent special disorders which can only be recognised by histological investigation: (1) hypocellular MDS, (2) MDS with fibrosis, and (3) MDS associated with systemic mastocytosis (SM) in the setting of a so-called SM-AHNMD (“associated clonal hematologic non-mast cell disorder”). While cytological atypia of blood cells is easilyrecognisable in smear preparations only histologic investigation of the bone marrow enables detection of reticulin fibrosis, small blast cell infiltrates and clustering of megakaryocytes. Therefore, immunohistochemical analysis with antibodies against the stem cell-associated antigen CD34, at least one platelet-related antibody (CD42, CD61), and an antibody against mast cell tryptase is recommended in all cases of suspected MDS. Differential diagnostic aspects include a broad variety of non-neoplastic and neoplastic disorders, especially overt acute myeloid leukemia (AML) but also systemic mastocytosis considering that more than one neoplasm may develop and co-exist in the same patient. KeywordsMyelodysplastic syndrome-Blast cells-Systemic mastocytosis-Immunohistochemistry
    03/2011: pages 25-41;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic myeloid leukemia (CML) is a hematopoietic neoplasm characterized by the Philadelphia chromosome and the related BCR-ABL1 oncoprotein. Acceleration of CML is usually accompanied by basophilia. Several proangiogenic molecules have been implicated in disease acceleration, including the hepatocyte growth factor (HGF). However, little is known so far about the cellular distribution and function of HGF in CML. We here report that HGF is expressed abundantly in purified CML basophils and in the basophil-committed CML line KU812, whereas all other cell types examined expressed only trace amounts of HGF or no HGF. Interleukin 3, a major regulator of human basophils, was found to promote HGF expression in CML basophils. By contrast, BCR-ABL1 failed to induce HGF synthesis in CML cells, and imatinib failed to inhibit expression of HGF in these cells. Recombinant HGF as well as basophil-derived HGF induced endothelial cell migration in a scratch wound assay, and these effects of HGF were reverted by an anti-HGF antibody as well as by pharmacologic c-Met inhibitors. In addition, anti-HGF and c-Met inhibitors were found to suppress the spontaneous growth of KU812 cells, suggesting autocrine growth regulation. Together, HGF is a BCR-ABL1-independent angiogenic and autocrine growth regulator in CML. Basophils are a unique source of HGF in these patients and may play a more active role in disease-associated angiogenesis and disease progression than has so far been assumed. Our data also suggest that HGF and c-Met are potential therapeutic targets in CML.
    Neoplasia (New York, N.Y.) 07/2012; 14(7):572-84. · 5.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An increase in eosinophils, basophils, and/or mast cells in the bone marrow may pose considerable diagnostic problems for the hematopathologist. In a first step, it is crucial to classify these changes as either being reactive or neoplastic. A slight increase in eosinophils is often seen in reactive states of myeloid hyperplasia while an increase in basophils is usually indicative of a neoplastic hematologic disorder. Regarding mast cells, the presence of compact infiltrates is the major criterion for systemic mastocytosis whereas a diffuse interstitial increase is often encountered in reactive states of mast cell hyperplasia. When a neoplastic disorder is diagnosed, definitive classification depends on immunohistochemical, molecular, and cytogenetic markers. The use of a limited panel of antibodies against basophil-, eosinophil-, and mast cell-related antigens like 2D7, eosinophil major basic protein, tryptase, and CD117 (KIT) is sufficient to identify diffuse or compact infiltrates and to provide semiquantitative analysis of accumulations of neoplastic or reactive cells. We therefore recommend the use of such markers which may increase the value of hematopathologic investigations and thereby are of major help to improve diagnosis and prognostication in these patients. KeywordsBasophilic leukemia–Basophils–Bone marrow–Eosinophilic leukemia–Eosinophils–Mast cells–Mastocytosis–Myeloproliferative neoplasm with eosinophilia–Systemic mastocytosis
    06/2011; 4(2):101-111.

Full-text (2 Sources)

Download
44 Downloads
Available from
May 21, 2014